Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape.
Mary E HallHeather L HuelsterAmy N LuckenbaughAaron A LavianaKirk A KeeganZachary KlaassenKelvin A MosesChristopher J D WallisPublished in: OncoTargets and therapy (2020)
Treatment options for patients with mHSPC are rapidly changing following years of stagnation. A number of systemic therapies offer benefit without significant clinical differences between them. The role for local treatment of the prostate as well as metastatic sites continues to evolve.